![Ran Weinstock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ran Weinstock
No más puestos en curso
Historial de carrera de Ran Weinstock
Antiguos cargos conocidos de Ran Weinstock.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Director/Miembro de la Junta | 31/07/2018 | - |
Independent Dir/Board Member | 31/07/2018 | - |
Formación de Ran Weinstock.
Tel-Aviv University | Undergraduate Degree |
Netanya Academic College | Graduate Degree |
Bar-Ilan University | Graduate Degree |
Estadísticas
Internacional
Israel | 5 |
Operativa
Graduate Degree | 2 |
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Sectorial
Consumer Services | 4 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- Ran Weinstock
- Experiencia